




RealRate

PHARMACEUTICAL 2022

Turning Point Therapeutics Inc.
Rank 128 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

Turning Point Therapeutics Inc. Rank 128 of 475



The relative strengths and weaknesses of Turning Point Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Turning Point Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 194% points. The greatest weakness of Turning Point Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 293% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	992,462
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,089
Liabilities, Non-Current	0
Other Assets	7,179
Other Compr. Net Income	-1,483
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	3,822
Research and Development	192,979
Revenues	32,278
Selling, General and Administrative Expense	75,850

Output Variable	Value in 1000 USD
Assets	1,003,463
Liabilities	47,089
Expenses	268,829
Stockholders Equity	956,374
Net Income	-236,551
Comprehensive Net Income	-237,292
Economic Capital Ratio	17%

